NewAmsterdam Pharma Co NV 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period fromtoCommission File Number: 001-41562 NewAmsterdam Pharma Company N.V.(Exact Name of Registrant as Specified in its Charter) The Netherlands( State or other jurisdiction ofincorporation or organization)Gooimeer 2-35NaardenThe Netherlands(Address of principal executive offices) Registrant’s telephone number, including area code: +31 (0) 35 206 2971 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☒Non-accelerated filer☐Emerging growth company☐ Accelerated filer☐Smaller reporting company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of April 29, 2026, the registrant had 116,903,979 ordinary shares, nominal value €0.12 per share, outstanding. Table of Contents Item 1.Financial Statements (Unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of Comprehensive LossCondensed Consolidated Statements of Shareholders' EquityCondensed Consolidated Statements of Cash FlowsNotes to Unaudited Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II.OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures Unless otherwise stated or the context otherwise indicates, references to “we,” “our,” “us” or the “Company” refer toNewAmsterdam Pharma Company N.V., together with its subsidiaries. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (“Quarterly Report”) contains forward-looking statements. Forward-looking statementsprovide the Company’s current expectations or forecasts of future events. Forward-looking statements include statements about theCompany’s expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Wordsor phrases such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,”“ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will” and “would,” or similar words or phrases, or the negatives ofthose words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that astatement is not forward-looking. Examples of forward-looking statements in this Quarterly Report include, but are not limited to,statements regarding the Company’s future operations, cash flows, financial position, dividend policy, prospects, strategies,objectives and other future events. Forward-looking statements in this Quarterly Report and in any document incorporated by reference in this Quarterly Reportmay include, for example, statements about: •the potential liquidity and trading of the Company’s public securities;•the Company’s ability to raise additional capital in sufficient amounts or on terms acceptable to it;•the efficacy and safety of the Company’s product candidates, obicetrapib as a monotherapy and as a fixed-dosecombination therapy with ezetimibe, as well as potential regulatory approvals and product launches, potentialreimbursement and anticipated market size and market opportunity;•the Company’s dependence on the success of obicetrapib as a monothera